Skip to content

Endoscopic Long Volume Reduction by Endobronchial Valves in Belgium

Endoscopic Long Volume Reduction by Endobronchial Valves in Belgium

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03264768
Acronym
BEVA
Enrollment
40
Registered
2017-08-29
Start date
2017-08-01
Completion date
2020-12-31
Last updated
2019-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

valves, Chronic Obstructive Pulmonary Disease, endoscopic long volume reduction

Brief summary

This a single center non-randomised non-sham controlled intervention study evaluating the effectiveness and safety of endoscopic lung volume reduction by endobronchial valves

Detailed description

The primary objective of the current study is to explore the effect of targeted lobar endobronchial lung volume reduction in symptomatic patients with severe emphysema and absent collateral ventilation, on lung function, exercise capacity and physical activity. As a secondary objective, changes in physical activity as result of a 3 month activity coaching program delivered between 3 to 6 months post intervention will be investigated. Exploratory objectives are to extend insight in the clinical characteristics of responders and non-responders and to address relationships between lung function response, physical functioning and its impact on inflammation, skeletal and cardiac function. Furthermore, comparison of the effects on lung function, exercise capacity, quality of life and physical activity between endoscopic lung volume reduction and surgical lung volume reduction will be made. The study will also explore if treatment response can be optimised by an intermediate evaluation with CT scan one month after intervention. Endoscopic evaluation and repositioning of the endobronchial valves will be imposed in case no lober atelectasis is visualised. .

Interventions

A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.

BEHAVIORALphysical activity tele coaching

3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.

PROCEDURELung volume reduction surgery (LVRS)

Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.

Sponsors

KU Leuven
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 40 - 75 years * Confluent or destructive heterogeneous emphysema on CT * Smoking cessation for at least 6m (proven by urinary cotinine levels) * FEV1 \< 60 %predicted, RV \> 150 %predicted, TLC \> 90 %predicted * RV/TLC ratio ≥ 0.55 * 6MWD \< 450 meter * mMRC ≥ 2 * Visual estimation of 70% complete fissure between target lobe and adjacent lobe on CT of referring physician * LABA-LAMA bronchodilator therapy as a minimum therapy * Able to sign informed consent

Exclusion criteria

* Homogenous emphysema * PaCO2 \> 60 mmHg with ambient air * PaO2 \< 45 mmHg with ambient air * Previous LVRS, lung transplantation, lobectomy * TLCO or FEV1 \< 20% predicted * Significant pulmonary hypertension (PaPsyst \> 50 mm Hg) * Heart failure with reduced EF (\< 40%) * 6MWD \< 100 meter * BODE index ≥ 7 and eligible for transplantation * Active cancer * Life expectancy \< 3 months * Significant lung disease other than COPD/emphysema * Unable to comply with study procedures

Design outcomes

Primary

MeasureTime frameDescription
response rate of FEV1 at 3 months post intervention3 monthsproportion of patients with a minimal change of FEV1 \> 100 ml

Secondary

MeasureTime frameDescription
response rate on SGRQ at 3 months and 6 months post intervention3 months and 6 months post interventionproportion of patients with a minimal change of -4 points on SGRQ
response rate on 6 minutes walking distance (6MWD) at 3 months and 6 months post intervention3 months and 6 months post interventionproportion of patients with a minimal improvement of 30 meters on 6MWD
response rate on residual volume (RV) at 3 months and 6 months post intervention3 months and 6 months post interventionproportion of patients with a minimal reduction of 400 ml on residual volume
response rate on FEV1 at 6 months post intervention6 monthsproportion of patients with a minimal change of FEV1 \> 100 ml
response rate on Transitional dyspnee index (TDI) at 3 months and 6 months post intervention3 months and 6 months post interventionproportion of patients with a minimal change of -1 point on TDI

Other

MeasureTime frameDescription
changes in physical activity between 3 and 6 months of follow up (telecoaching period)3 months - 6 months post allocationAbsolute difference in stepcounts per day (n) 3 months - 6 months post allocation
changes in ProActive clinical visit questionnaire between 3 and 6 months of follow up (telecoaching period)3 months - 6 months post allocationAbsolute difference in points 3 months - 6 months post allocation
Comparing change in FEV1 (liters), FVC (liters), RV (liters), TLC (liters) at 3 and 6 months post EBV and LVRS3 months and 6 months post intervention (endoscopic or surgical)Absolute difference from baseline values (liters) for both interventions
Change in FEV1 (liters), FVC (liters), RV (liters), TLC (liters) at 3 and 6 months post intervention3 months and 6 months post interventionAbsolute difference from baseline values (liters)
Comparing change in physical activity at 3 and 6 months post EBV and LVRS3 months and 6 months post intervention (endoscopic or surgical)Absolute difference from baseline values (amount of steps per day) for both interventions
Comparing change in SGRQ at 3 and 6 months post EBV and LVRS3 months and 6 months post intervention (endoscopic or surgical)Absolute difference from baseline values for both interventions
Comparing change in 6MWD at 3 and 6 months post EBV and LVRS3 months and 6 months post intervention (endoscopic or surgical)Absolute difference from baseline values (meters) for both interventions
Change in RV/TLC ratio (%) at 3 and 6 months post intervention3 months and 6 months post interventionAbsolute difference from baseline values (%)
Change in 6MWD (meters) at 3 and 6 months post intervention3 months and 6 months post interventionAbsolute difference from baseline values (meters)
Change in physical activity at 3 months post intervention3 months post interventionAbsolute difference in stepcounts per day (n) from baseline values
Change in ProActive clinical visit questionnaire3 months post interventionAbsolute difference in points from baseline values
Change in BODE index3 months and 6 months post interventionAbsolute difference in points from baseline values

Countries

Belgium

Contacts

Primary ContactKaren Denaux, sc, nurse
karen.denaux@uzleuven.be016 34 19 66
Backup ContactKristien De Bent, sc
krisiten.debent@uzleuven.be016 34 17 01

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026